KRAS and neoplasm: Consistent with mouse Kras tumor data, there appeared to be a significant downregulation of anti-tumor immune responses and decrease in IFN signaling genes such as IFITM1 in MGA-altered cases (Figure 7A,B, Figure 7—figure supplement 1D).